Gotowe bibliografie tematyczne / Angiotensin Inhibitors

Spis treści

  1. Artykuły w czasopismach
  2. Rozprawy doktorskie
  3. Książki
  4. Części książek
  5. Streszczenia konferencji
  6. Raporty organizacyjne

Gotowa bibliografia na temat „Angiotensin Inhibitors”

Autor: Grafiati
Data publikacji: 3 czerwca 2025
Data aktualizacji: 31 lipca 2025

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Angiotensin Inhibitors”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Angiotensin Inhibitors"

1

Roshanov, Pavel S., Bram Rochwerg, Ameen Patel, et al. "Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery." Anesthesiology 126, no. 1 (2017): 16–27. http://dx.doi.org/10.1097/aln.0000000000001404.

Pełny tekst źródła
Streszczenie:
Abstract Background The effect on cardiovascular outcomes of withholding angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in chronic users before noncardiac surgery is unknown. Methods In this international prospective cohort study, the authors analyzed data from 14,687 patients (including 4,802 angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker users) at least 45 yr old who had in-patient noncardiac surgery from 2007 to 2011. Using multivariable regression models, the authors studied the relationship between withholding angiotensin-converting e
Style APA, Harvard, Vancouver, ISO itp.
2

Farag, Ehab, Chen Liang, Edward J. Mascha, et al. "Association between Use of Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers and Postoperative Delirium." Anesthesiology 133, no. 1 (2020): 119–32. http://dx.doi.org/10.1097/aln.0000000000003329.

Pełny tekst źródła
Streszczenie:
Background Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers improve cognitive function. The authors therefore tested the primary hypothesis that preoperative use of angiotensin inhibitors is associated with less delirium in critical care patients. Post hoc, the association between postoperative use of angiotensin system inhibitors and delirium was assessed. Methods The authors conducted a single-site cohort study of adults admitted to Cleveland Clinic critical care units after noncardiac procedures between 2013 and 2018 who had at least one Confusion Assessment Method
Style APA, Harvard, Vancouver, ISO itp.
3

Brar, Sandeep, Kathleen D. Liu, Alan S. Go, et al. "Prospective Cohort Study of Renin-Angiotensin System Blocker Usage after Hospitalized Acute Kidney Injury." Clinical Journal of the American Society of Nephrology 16, no. 1 (2020): 26–36. http://dx.doi.org/10.2215/cjn.10840720.

Pełny tekst źródła
Streszczenie:
Background and objectivesThe risk-benefit ratio of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after AKI may be altered due to concerns regarding recurrent AKI. We evaluated, in a prospective cohort, the association between use (versus nonuse) of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and the subsequent risk of AKI and other adverse outcomes after hospitalizations with and without AKI.Design, setting, participants, & measurementsWe studied 1538 patients recently discharged from the hospital who enrolled in the multicenter,
Style APA, Harvard, Vancouver, ISO itp.
4

Čertíková Chábová, Věra. "Angiotensin converting enzyme inhibitors in nephrology." Klinická farmakologie a farmacie 33, no. 4 (2020): 35–38. http://dx.doi.org/10.36290/far.2019.030.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Li, Ruyin, Tongtong Tang, Feifei Ma, et al. "Identification of Three Novel Angiotensin-I-Converting Enzyme Inhibitory Peptides from Cassia Obtusifolia Seeds and Evaluation of their Inhibition Mechanisms." Current Topics in Nutraceutical Research 22, no. 1 (2023): 108–15. http://dx.doi.org/10.37290/ctnr2641-452x.22:108-115.

Pełny tekst źródła
Streszczenie:
Angiotensin-I-converting enzyme inhibitory peptides were isolated from Cassia obtusifolia seeds by alcalase hydrolysis. Using ultrafiltration, the peptides were divided into four fractions (<1, 1–3, 3–5, >5 kDa). The fraction below 1 kDa exhibited the appropriate ACE inhibition (IC50 = 65.88 μg/mL), and was further purified by gel filtration chromatography, which displayed better angiotensin-I-converting enzyme inhibitory activity (IC50 = 53.67 μg/mL). The amino acid sequences of three novel angiotensin-I-converting enzyme inhibitory peptides were identified by liquid chromatography with
Style APA, Harvard, Vancouver, ISO itp.
6

Lazar, Angela Madalina. "Renin-angiotensin-aldosterone system inhibitors – a realm of confusion in COVID-19." Journal of Ideas in Health 4, Special2 (2021): 389–94. http://dx.doi.org/10.47108/jidhealth.vol4.issspecial2.125.

Pełny tekst źródła
Streszczenie:
Currently, there is a persisting dispute regarding the renin-angiotensin-aldosterone-system (RAAS) inhibitors' safety of use in COVID-19 pandemics. On one side, RAAS inhibitors appear to determine an overexpression of ACE2, the receptor of SARS-CoV-2. Therefore, they could increase the risk of SARS-CoV-2 infection and its degree of severity. On the other side, the discontinuation of RAAS leads to cardiovascular decompensation and has been discouraged by the major medical societies. Also, large-cohort studies report beneficial or at least neutral effects for the RAAS inhibitors in COVID-19 pati
Style APA, Harvard, Vancouver, ISO itp.
7

Warner, Kelly K., James A. Visconti, and Marva M. Tschampel. "Angiotensin II Receptor Blockers in Patients with ACE Inhibitor–Induced Angioedema." Annals of Pharmacotherapy 34, no. 4 (2000): 526–28. http://dx.doi.org/10.1345/aph.19294.

Pełny tekst źródła
Streszczenie:
OBJECTIVE: To determine the safety of using angiotensin II receptor blockers in patients who have experienced angioedema following treatment with angiotensin-converting enzyme (ACE) inhibitors. DATA SOURCES: Clinical literature identified through MEDLINE (January 1966–August 1999). Key search terms included angioneurotic edema, angiotensin-converting enzyme inhibitors, receptors–angiotensin, and losartan. DATA SYNTHESIS: ACE inhibitor–induced angioedema occurs with an incidence of 0.1–0.5%. Alternative therapy is necessary for patients who experience this potentially life-threatening adverse e
Style APA, Harvard, Vancouver, ISO itp.
8

Mets, Berend, and Edward D. Miller. "Angiotensin and angiotensin-converting enzyme inhibitors." Baillière's Clinical Anaesthesiology 8, no. 1 (1994): 151–73. http://dx.doi.org/10.1016/s0950-3501(05)80142-4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Leclézio, Alexandra, Jared Robinson, and Indrajit Banerjee. "SARS-CoV-2: ACE inhibitors, disastrous or desirable?" Journal of Biomedical Sciences 7, no. 1 (2020): 40–46. http://dx.doi.org/10.3126/jbs.v7i1.29852.

Pełny tekst źródła
Streszczenie:
Background: The world has a current total of 6,663,304 confirmed cases of COVID-19 with a death count of 392,802 deaths according to the WHO (6 June 2020). Various risk factors for the acquisition and subsequent development of deadly complications due to the virus have been established. One such risk factor is the presence of cardiovascular disease, particularly hypertension as a comorbidity. It must be noted that JNC 8 advise the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers as first line drugs for the management of hypertension. ARDS is caused by the activa
Style APA, Harvard, Vancouver, ISO itp.
10

Shunan, Fan, Yuan Jiqing, and Dong Xue. "Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials." Journal of the Renin-Angiotensin-Aldosterone System 19, no. 4 (2018): 147032031880349. http://dx.doi.org/10.1177/1470320318803495.

Pełny tekst źródła
Streszczenie:
Objective: The efficacy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in reducing cardiovascular outcomes in patients with diabetes and overt nephropathy is still a controversial issue. Methods: We systematically searched MEDLINE, Embase and Cochrane Library for randomised controlled trials. Results: Thirteen trials containing 4638 patients with diabetes and overt nephropathy were included. Compared with controls, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker treatment did not reduce the risk of cardiovascular events (odds ratio 0.94, 95%
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Angiotensin Inhibitors"

1

Hughes, M. A. "Metal binding by some angiotensin converting enzyme inhibitors." Thesis, Cardiff University, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.305894.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Dičkutė, Asta. "Trends in the use of Angiotensin converting enzyme inhibitors and Angiotensin II antagonists in Lithuania on 2005-2007 years." Master's thesis, Lithuanian Academic Libraries Network (LABT), 2008. http://vddb.library.lt/obj/LT-eLABa-0001:E.02~2008~D_20080616_100311-96511.

Pełny tekst źródła
Streszczenie:
Objective: To evaluate the tendencies of utilization of Angiotensin converting enzyme inhibitors and Angiotensin II receptors antagonists in Lithuania during 2005-2007 years. Methods: MEDLINE database was searched to identify and evaluate all literature relating to pharmacokinetic and pharmacodynamic characteristics of Angiotensin converting enzyme inhibitors and Angiotensin II antagonists. Utilization data of Angiotensin converting enzyme inhibitors (plain and combinations) and Angiotensin II antagonists (plain and combinations) in Lithuania over three years (2005 – 2007) period were obtaine
Style APA, Harvard, Vancouver, ISO itp.
3

Brice, Edmund Andrew William. "Rat angiotensin-converting enzyme : tissue specific expression during pharmacological inhibition." Doctoral thesis, University of Cape Town, 1995. http://hdl.handle.net/11427/27042.

Pełny tekst źródła
Streszczenie:
The renin-angiotensin system plays a central role in the maintenance of blood pressure. Angiotensin II, the main effector of this system, results from the action of angiotensin-converting enzyme (ACE) on angiotensin I. Angiotensin II, maintains vasomotor tone via its vasoconstrictor action, and also increases salt and water retention by stimulating the release of aldosterone. ACE inhibitors, such as captopril, enalapril and lisinopril, are highly effective in the treatment of hypertension and congestive cardiac failure. Previous studies have suggested that angiotensin converting enzyme (ACE) p
Style APA, Harvard, Vancouver, ISO itp.
4

Coltart, Donald M. "Synthetic studies on angiotensin-converting enzyme inhibitors, pyridines, and peptides." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape2/PQDD_0014/NQ59572.pdf.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Longman, S. D. "Cardiovascular studies with angiotensin converting enzyme inhibitors in the rat." Thesis, University of Bradford, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.375102.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Ajayi, A. A. L. "Clinical and pharmacological studies on angiotensin-I-converting enzyme inhibitors." Thesis, University of Glasgow, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.374510.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Christian, Jennifer B. "Beyond the antihypertensive effect: ACE inhibitors and angiotensin receptor blockers." View abstract/electronic edition; access limited to Brown University users, 2008. http://gateway.proquest.com/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:3318302.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Lee, Alison Frances Clare. "The renin angiotensin aldosterone axis : relationships with other hormone systems, and novel applications for angiotensin converting enzyme inhibitors." Thesis, University of Edinburgh, 2000. http://hdl.handle.net/1842/22401.

Pełny tekst źródła
Streszczenie:
The aim of this thesis was to look at the renin angiotensin system both in clinical heart failure, and in relation to other physiological systems where an interaction may exist. Furthermore, to address new areas where a potential for benefit with Angiotensin Converting Enzyme (ACE) inhibitors might occur. To this end there are five studies discussed within the thesis. It is shown that in a group of heart failure patients, stabilised on maximum tolerated dose of ACE inhibitor, mean levels of plasma neurohormones were remarkably stable over 18 months. Reactivation of aldosterone occurred in 13/9
Style APA, Harvard, Vancouver, ISO itp.
9

Chadwick, Ian George. "Studies on the angiotensin converting enzyme gene polymorphism and ACE inhibitors." Thesis, University of Edinburgh, 1997. http://hdl.handle.net/1842/21136.

Pełny tekst źródła
Streszczenie:
Angiotensin converting enzyme (ACE) converts angiotensin I to angiotensin II, an important step in the control of blood pressure. The gene encoding for ACE is subject to an insertion/deletion (I/D) polymorphism which is associated with different levels of the enzyme in serum. This polymorphism accounts for 47% of the variability in serum ACE concentrations between subjects but its relevance to tissue ACE is unknown. ACE inhibition increases kinin level, for example bradykinin. Kinins have been proposed be involved in the pathogenesis of cough due to ACE inhibitors, a common adverse effect in t
Style APA, Harvard, Vancouver, ISO itp.
10

Titus, Timothy. "Utilization of Angiotensin-Converting-Enzyme Inhibitors in the Treatment of Diabetics Within an Out-Patient Care Facility." The University of Arizona, 2005. http://hdl.handle.net/10150/624773.

Pełny tekst źródła
Streszczenie:
Class of 2005 Abstract<br>Objective: The purpose of this study was to retrospectively determine if individuals within the SAVAHCS home-based patient population with a diagnosis of diabetes mellitus are receiving an angiotensin-converting-enzyme inhibitor (ACE-I) based on recent evidence supporting its use in these patients. Research Design: A retrospective, chart review of 41 patients with a diagnosis of diabetes mellitus from November 1, 2004 to December 31, 2005. Methodology: This was a retrospective, chart review of all patients within the SAVAHCS home-based population with an active diag
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Angiotensin Inhibitors"

1

B, Kostis John, and DeFelice Eugene A, eds. Angiotensin converting enzyme inhibitors. Liss, 1987.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

N, DeBrue Anne, ed. Angiotensin converting enzyme inhibitors. Nova Biomedical Books, 2009.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

K, Ferguson Roger, and Vlasses Peter, eds. Angiotensin-converting enzyme inhibitors. Futura Pub. Co., 1987.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Nandave, Mukesh, ed. Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-7380-0.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

J, Whalley Lawrence, ed. ACE inhibitors: Central actions. Raven Press, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

1957-, D'Orléans-Juste P., and Plante G. E, eds. ACE inhibitors. Birkhäuser Verlag, 2001.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

S, Dhalla Naranjan, and Manitoba Cardovascular Forum on Angiotensin Receptor Blockade (1996 : Winnipeg, Man.), eds. Angiotensin II receptor blockade: Physiological and clinical implications. Kluwer Academic Publishers, 1998.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

L, Clement Denis, ed. Angiotensin converting enzyme inhibitors: Past, present and beyond. Royal Society of Medicine Services, 1989.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

A, MacGregor G., and Sever Peter S, eds. Current advances in ACE inhibition 2: Proceedings of an Internationalsymposium, Queen Elizabeth II Conference Centre, London, UK 17-21 February 1991. Churchill Livingstone, 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Graham, MacGregor, Sever Peter S, International Symposium on ACE Inhibition (1st : 1989 : London, England), and International Symposium on ACE Inhibition (2nd : 1991 : London, England), eds. Current advances in ACE inhibition. Churchill Livingstone, 1989.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Angiotensin Inhibitors"

1

Gohlke, P., and B. A. "ACE Inhibitors: Pharmacology." In Angiotensin Vol. II. Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18497-0_17.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Hurley, Seth. "Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)." In Encyclopedia of Behavioral Medicine. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-39903-0_1210.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Abrams, David B., J. Rick Turner, Linda C. Baumann, et al. "Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)." In Encyclopedia of Behavioral Medicine. Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_1210.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Plante, Gérard E., and Tewfik Nawar. "Angiotensin converting enzyme inhibition in the microcirculation." In ACE Inhibitors. Birkhäuser Basel, 2001. http://dx.doi.org/10.1007/978-3-0348-7579-0_7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Özkaya, Esen, and Kurtuluş Didem Yazganoğlu. "Angiotensin-Converting Enzyme Inhibitors." In Adverse Cutaneous Drug Reactions to Cardiovascular Drugs. Springer London, 2014. http://dx.doi.org/10.1007/978-1-4471-6536-1_2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Mountokalakis, Theodore D. "Angiotensin Converting Enzyme Inhibitors." In Contemporary Concepts in Cardiology. Springer US, 1999. http://dx.doi.org/10.1007/978-1-4615-5007-5_12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Frishman, William H., Angela Cheng-Lai, and Julie Chen. "Angiotensin-Converting Enzyme Inhibitors." In Current Cardiovascular Drugs. Current Medicine Group, 2000. http://dx.doi.org/10.1007/978-1-4615-6767-7_4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Gavras, Irene, and Haralambos Gavras. "Angiotensin-Converting Enzyme Inhibitors." In Hypertension Medicine. Humana Press, 2001. https://doi.org/10.1007/978-1-59259-008-7_28.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Nandave, Mukesh. "ACE Inhibitors: Preferred RAAS Inhibitor in High-Risk Patients as Compared to ARBs." In Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers. Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-97-7380-0_3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Schiffrin, E. L. "Renin-Angiotensin Inhibitors and Vascular Effects." In Angiotensin Vol. II. Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18497-0_4.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Angiotensin Inhibitors"

1

Fejril, Atilla, and Isman Kurniawan. "Prediction of Angiotensin-Converting-Enzyme (ACE) Inhibitors as Antihypertensive Agents Using Artificial Neural Network Optimized by Artificial Bee Colony." In 2025 International Conference on Computer Sciences, Engineering, and Technology Innovation (ICoCSETI). IEEE, 2025. https://doi.org/10.1109/icocseti63724.2025.11019267.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Bayan, Raihan Fathul, and Isman Kurniawan. "Implementation of Camel Algorithm-Support Vector Machine in Predicting Angiotensin Converting Enzyme (ACE) Inhibitor as Antihypertensive Agent." In 2025 International Conference on Advancement in Data Science, E-learning and Information System (ICADEIS). IEEE, 2025. https://doi.org/10.1109/icadeis65852.2025.10933060.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Chae, Y., M. Valsecchi, A. Lucca, J. Kim, and A. Desai. "Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers May Reduce Breast Cancer Recurrence." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-3121.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

MATTOS, ARTHUR FIOROTTO DE, NATHALIA SILVEIRA BARSOTTI, and RAFAEL RIBEIRO ALMEIDA. "RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS AND COVID-19 COMPLICATIONS." In II Brazilian Congress of Health. HEALTH2021, 2021. http://dx.doi.org/10.51162/health2021-0001.

Pełny tekst źródła
Streszczenie:
The world faces today a pandemic of unquestionable importance, caused by an infection with a new enveloped RNA virus that belongs to the Coronaviridae family. The new coronavirus (SARS-CoV 2) uses a glycoprotein present on its surface to bind to and infect host cells that express the angiotensin converting enzyme II (ACE-2). Although different tissues may be targeted by the virus, respiratory complications remain as the main cause of death. It has been demonstrated that Renin-Angiotensin-Aldosterone System (RAAS) inhibitors increase ACE-2 expression in animal models, raising the concern that p
Style APA, Harvard, Vancouver, ISO itp.
5

Ekart, Robert, Nejc Piko, Luka Varda, Tadej Petreski, Sebastjan Bevc, and Radovan Hojs. "The role of sacubitril/valsartan in patients with advanced chronic kidney disease and heart failure." In 7th International Congress of Cardionephrology KARNEF 2025. Punta Niš, 2025. https://doi.org/10.46793/karnef25.136e.

Pełny tekst źródła
Streszczenie:
Chronic kidney disease and heart failure (HF) are closely related conditions that often coexist and complicate each other. Both conditions can exacerbate disease progression and influence treatment strategies. Angiotensin receptor- neprilysin inhibitors (ARNIs) are playing an increasingly important role in the treatment of HF. ARNIs combine two mechanisms of action: sacubitril is a neprilysin inhibitor that enhances natriuretic peptides, resulting in vasodilation, diuresis and reduced cardiac workload; valsartan is an angiotensin II receptor blocker that reduces the effects of the renin-angiot
Style APA, Harvard, Vancouver, ISO itp.
6

de Lacerda, Dhiego Alves, Pedro Fechine Honorato, Renata Braga Vale, et al. "Role of Angiotensin Converting Enzyme Inhibitors (ACEIs) in Heart Failure: Mechanism of Action and Benefits of ACEIs." In III Seven International Medical and Nursing Congress. Seven Congress, 2024. http://dx.doi.org/10.56238/iiicongressmedicalnursing-036.

Pełny tekst źródła
Streszczenie:
INTRODUCTION: Heart failure is a chronic condition characterized by the inability of the heart to pump blood effectively. Angiotensin-converting enzyme inhibitors (ACEIs) are essential in the treatment of this condition, due to their vasodilatory, antihypertensive and cardioprotective effects. OBJECTIVE: This summary explores the mechanism of action of ACEIs and the benefits associated with their use in the management of heart failure, based on information from renowned academic sources. METHODOLOGY: A literature review was performed using works such as: Goodman and Gilman's The Pharmacologica
Style APA, Harvard, Vancouver, ISO itp.
7

Chavoshian, S., S. Saha, and J. Cafazzo. "The Effect of Angiotensin-Converting Enzyme Inhibitors Therapy on Quality of Sleep." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2668.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Yalcin, Huseyin C., Mohamed A. Elrayess, Hadeel T. Al-Jighefee, Mahmoud Khatib A. A. Al-Ruweidi, Shamma Almuraikhy, and Hadi M. Yassine. "Soluble ACE2 and Angiotensin II levels Modulated in Hypertensive COVID-19 Patients treated with different Antihypertension Drugs." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0085.

Pełny tekst źródła
Streszczenie:
Hypertension is a major risk factor and common comorbidity among severe Coronavirus Disease 2019 (COVID-19) patients. Prominent antihypertensive drugs, such as angiotensin-converting-enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) can modulate the expression of angiotensin-converting enzyme 2 (ACE2) and may influence COVID-19 prognosis. Other classes of antihypertensive drugs, such as beta-blockers (BB) and calcium channel blockers (CCB) are associated with reduced mortality. Still, their effect on the circulating levels of ACE2 and angiotensin II, as well as the severity of C
Style APA, Harvard, Vancouver, ISO itp.
9

Watkins, Timothy R., Luciano B. Lemos-Filho, Ousama Dabbagh, Steven Y. Chang, Pauline K. Park, and MIchelle N. Gong. "Use Of Angiotensin Converting Enzyme Inhibitors Or Angiotensin Receptor Blockers And Clinical Outcomes Among Patients At-risk For Acute Lung Injury." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5598.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Arnaout, Karim, Shatha Farhan, Jatin Rana, Michelle Jankowski, and Ding Wang. "Abstract B93: Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers may decrease cancer‐related mortality in patients with small‐cell lung cancer." In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Dec 6–9, 2009; Houston, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1940-6207.prev-09-b93.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Angiotensin Inhibitors"

1

Pletcher, Mark, Steve Smith, Madelaine Modrow, and Rhonda Dehoff. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with COVID-19 Outcomes in Patients with Hypertension. Patient-Centered Outcomes Research Institute® (PCORI), 2022. http://dx.doi.org/10.25302/05.2022.pacr.2017c28153-c19.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Yao, Jia, Xiayu Gong, Xiaoyan Shi, Simin Fan, Junmin Chen, and Qiu Chen. The efficacy of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on insulin resistance in hypertensive patients：A protocol for a systematic review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.5.0032.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Shen, Jinhai, Bowen Liang, Yun Wang, and Yong Yang. Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.11.0136.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Wu, Xiaoqi, Jisen Zhao, Maoxia Fan, and Dongo Guo. Quality of Evidence Supporting the Effects of Xinmailong injection in Heart Failure: An Overview of Systematic Reviews and Meta-Analyses. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.10.0023.

Pełny tekst źródła
Streszczenie:
Review question / Objective: 2.1.1 type of research SRs/MAs of RCT (randomized controlled trial) of Xinmailong injection for the treatment of heart failure. 2.1.2 Subject investigated All included patients met internationally recognized diagnostic criteria for heart failure.There are no limitations on age, gender, ethnicity, time of onset, source of cases and language of publication. 2.1.3 Type of Intervention The control group was treated with conventional basic Western medicine recommended by the guidelines related to heart failure[1, 11], including antiplatelet drugs, anticoagulants, vasodi
Style APA, Harvard, Vancouver, ISO itp.
5

Yuan, Shizhu, Yueming Liu, and Qiang He. Association between early worsening of renal function and poor outcomes in patients treated with renin angiotensin system inhibitors: A meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.7.0064.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

กาญจนทัต, อภิชาติ. โปรตีนไฮโดรไลเสตจากเมล็ดผลไม้ไทยเพื่อการบำบัดโรค : รายงานวิจัยฉบับสมบูรณ์ (ปีที่ 1). จุฬาลงกรณ์มหาวิทยาลัย, 2014. https://doi.org/10.58837/chula.res.2014.89.

Pełny tekst źródła
Streszczenie:
Blood pressure regulation is partially dependent on the renin-angiotensin system; renin acts on angiotensinogen to release angiotensin-I, which is further converted into the angiotensin II by the angiotensin I-converting enzyme (ACE). ACE plays a key physiological role in the regulation of blood pressure by virtue of two different reactions that it catalyzes: conversion of the inactive angiotensin I to the powerful vasoconstrictor angiotensin II, and inactivation of the vasodilator bradykinin. Crude extract and ammonium sulphate cut protein extracts, and their pepsin-pancreatin hydrolysates, f
Style APA, Harvard, Vancouver, ISO itp.
7

Feng, Yu. Renal Safety and Efficacy of Angiotensin Receptor-neprilysin Inhibitor : a meta-analysis of Randomized Controlled Trials. INPLASY - International Platform of Registered Systematic Review Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.4.0115.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Zhang, Guoyue, and Yue Wu. The use of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor on severity or mortality in patients with COVID-19: A Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.9.0067.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Xue, Xue, Xin-yan Jin, Ke-ying Li, et al. Ophiocordyceps sinensis preparation combined with renin-angiotensin system inhibitor for diabetic kidney disease: an umbrella review of systematic reviews and network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.5.0066.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Dong, Zhenyu, Muyassar Yusup, Yanmei Lu, and Baopeng Tang. The effectiveness of angiotensin receptor-neprilysin inhibitor in ventricular arrhythmia in patients with Heart Failure with Reduced Ejection Fraction: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.9.0012.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Angiotensin Inhibitors” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii